- Record: found
- Abstract: found
- Article: not found
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Johannan F Brandse
1 ,
Gijs R van den Brink
1 ,
Manon E Wildenberg
2 ,
Desiree van der Kleij
3 ,
Theo Rispens
4 ,
Jeroen M Jansen
5 ,
Ron A Mathôt
6 ,
Cyriel Y Ponsioen
7 ,
Mark Löwenberg
7 ,
Geert R A M D'Haens
8
Aug 2015
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
It is not clear why some patients with ulcerative colitis (UC) do not respond to treatment with anti-tumor necrosis factor (TNF) agents, such as infliximab. It could be that some patients have high level of inflammation, with large quantities of TNF to be neutralized by the drug. We investigated whether loss of anti-TNF agents through ulcerated intestinal mucosa reduces the efficacy of these drugs in patients with severe UC.